← Sarepta Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $122.4m | $599.7m | $370.8m | $835.1m | $1.5b | $2.1b | $966.8m | $428.4m | $1.1b | $801.3m | |
| Cash, Cash Equivalents, and Short-term Investments | $329.3m | $1.1b | $1.2b | $1.1b | $1.9b | $2.1b | $2.0b | $1.7b | — | — | |
| Short-term Investments | $195.4m | $479.4m | $803.1m | $289.7m | $435.9m | $0 | $1.0b | $1.2b | $251.8m | $138.4m | |
| Inventory, Net | $12.8m | $83.6m | $125.4m | $171.4m | $232.0m | $186.2m | $204.0m | $322.9m | $750.0m | $914.7m | |
| Assets, Current | $373.5m | $1.2b | $1.4b | $1.5b | $2.5b | $2.6b | $2.6b | $2.6b | $3.1b | $2.5b | |
| Property, Plant and Equipment, Net | $37.8m | $43.2m | $97.0m | $129.6m | $190.4m | $191.2m | $180.0m | $227.2m | $340.3m | $345.1m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $37.9m | $91.8m | $45.5m | $65.0m | $130.0m | $148.3m | $125.5m | |
| Other Assets, Noncurrent | $4.0m | — | — | $173.9m | $203.7m | $292.9m | $317.9m | $136.8m | $79.9m | $155.6m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $5.2m | $29.5m | $49.0m | $90.9m | $101.3m | $153.0m | $214.6m | $400.3m | $602.0m | $398.2m | |
| Accrued Liabilities, Current | $31.0m | $69.0m | $134.1m | $185.5m | $193.6m | $271.7m | $419.0m | $315.0m | $373.5m | $359.7m | |
| Assets | $424.1m | $1.3b | $1.6b | $1.8b | $3.0b | $3.1b | $3.1b | $3.3b | $4.0b | $3.3b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $7.8m | $20.9m | $15.0m | $15.5m | $17.8m | $13.3m | $11.2m | |
| Accounts Payable, Current | $29.7m | $8.5m | $33.8m | $68.1m | $111.1m | $76.7m | $95.9m | $164.9m | $214.4m | $280.8m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $47.7m | $80.4m | $41.5m | $57.6m | $141.0m | $192.5m | $199.4m | |
| Deferred Revenue, Current | $3.3m | $3.3m | $3.3m | $3.3m | $89.2m | $89.2m | $89.2m | $50.4m | $130.3m | $443.4m | |
| Long-term Debt, Current Maturities | — | — | — | — | — | — | — | $105.5m | $0 | — | |
| Liabilities, Current | $75.4m | $88.3m | $173.7m | $264.8m | $416.0m | $452.7m | $619.6m | $653.7m | $731.7m | $1.1b | |
| Other Liabilities, Noncurrent | $5.9m | $5.5m | $15.6m | $10.2m | $19.8m | $11.0m | $42k | $3.0m | $1.8m | $1.5m | |
| Long-term Debt | $17.7m | $601.3m | $420.6m | $681.9m | $992.5m | $1.1b | $1.5b | $1.2b | $1.1b | $829.0m | |
| Liabilities | $87.4m | $518.7m | $609.8m | $1.0b | $2.2b | $2.2b | $2.7b | $2.4b | $2.4b | $2.2b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $5k | $6k | $7k | $8k | $8k | $9k | $9k | $9k | $10k | $11k | |
| Retained Earnings (Accumulated Deficit) | ($1.2b) | ($1.2b) | ($1.6b) | ($2.3b) | ($2.8b) | ($3.2b) | ($3.9b) | ($4.4b) | ($4.2b) | ($4.9b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($120k) | ($379k) | ($99k) | $50k | $3k | $20k | ($1.7m) | $918k | ($218k) | $272k | |
| Additional Paid in Capital, Common Stock | $1.5b | $2.0b | $2.6b | $3.1b | $3.6b | $4.1b | $4.3b | $5.3b | $5.7b | $6.0b | |
| Stockholders' Equity Attributable to Parent | $336.7m | $789.2m | $1.0b | $818.2m | $761.8m | $928.0m | $384.9m | $859.3m | $1.5b | $1.1b | |
| Liabilities and Equity | $424.1m | $1.3b | $1.6b | $1.8b | $3.0b | $3.1b | $3.1b | $3.3b | $4.0b | $3.3b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.